ACUMEN PHARMACEUTICALS SHARES DOWN 77.3% TO $0.52 PREMARKET AFTER CO'S ALZHEIMER'S DRUG MISSES PRIMARY ENDPOINT IN MID-STAGE TRIAL

Reuters · 5d ago

Please log in to view news